TY - JOUR
T1 - Advances in pharmacotherapy for tobacco dependence
AU - Foulds, Jonathan
AU - Burke, Michael
AU - Steinberg, Michael
AU - Williams, Jill M.
AU - Ziedonis, Douglas M.
N1 - Funding Information:
All authors are supported in part by a grant from the New Jersey Department of Health and Senior Services through New Jersey’s Comprehensive Tobacco Control Program.
Funding Information:
J Foulds has worked as a consultant and received honoraria from pharmaceutical companies involved in production of tobacco dependence treatment medications, as well as a variety of agencies involved in promoting health (e.g., WHO, NIH). He has also worked as an expert witness in litigation, including law suits against tobacco companies. M Burke receives support from the Association of Schools of Public Health and the American Legacy Foundation. M Steinberg has received honoraria from pharmaceutical companies involved in the production of tobacco dependence treatment medications, in order to conduct educational activities. J Williams is primarily supported by a National Institute of Drug Abuse (NIDA) K-award. DM Ziedonis receives research grant support from Janssen, Bristol-Myer Squibb, AstraZeneca, and Lilly Pharmaceutical. He is also the principal investigator on research grants from the National Institute of Drug Abuse (NIDA R01 DA15978-01 and NIDA R01 DA015537) and Substance Abuse and Mental Health Services Administration (SAMHSA KD1 TI12549-01).
PY - 2004/5
Y1 - 2004/5
N2 - The discovery that bupropion is an effective treatment for tobacco dependence has triggered a rapid increase in development of potential new non-nicotine pharmacotherapies, including bromocriptine, glucose, GTS-21, reboxetine, rimonabant, selegeline and varenicline. Successful new products will need to have excellent side-effect profiles in addition to proven efficacy. New faster delivery nicotine replacement products have the promise of addressing a broader list of indications, including treatment of nicotine withdrawal during temporary abstinence and long-term nicotine maintenance. Nicotine vaccines will need to demonstrate efficacy and also improve certain consumer acceptability characteristics (e.g., frequency of injections required) before they can become widely used and successful therapies. The best hope of improved treatment comes from combining existing and new pharmacotherapies with effective behavioural therapy.
AB - The discovery that bupropion is an effective treatment for tobacco dependence has triggered a rapid increase in development of potential new non-nicotine pharmacotherapies, including bromocriptine, glucose, GTS-21, reboxetine, rimonabant, selegeline and varenicline. Successful new products will need to have excellent side-effect profiles in addition to proven efficacy. New faster delivery nicotine replacement products have the promise of addressing a broader list of indications, including treatment of nicotine withdrawal during temporary abstinence and long-term nicotine maintenance. Nicotine vaccines will need to demonstrate efficacy and also improve certain consumer acceptability characteristics (e.g., frequency of injections required) before they can become widely used and successful therapies. The best hope of improved treatment comes from combining existing and new pharmacotherapies with effective behavioural therapy.
UR - http://www.scopus.com/inward/record.url?scp=2642580863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2642580863&partnerID=8YFLogxK
U2 - 10.1517/14728214.9.1.39
DO - 10.1517/14728214.9.1.39
M3 - Review article
C2 - 15155135
AN - SCOPUS:2642580863
SN - 1472-8214
VL - 9
SP - 39
EP - 53
JO - Expert Opinion on Emerging Drugs
JF - Expert Opinion on Emerging Drugs
IS - 1
ER -
